Working to Treat Mitochondrial Epilepsy – One Seizure at a Time

Print Friendly, PDF & Email

Robert F. Kennedy famously said, “The purpose of life is to contribute in some way to making things better.” And when you’re in the rare disease business, you measure how you’re “making things better” on a micro, but no less vital, scale.

For Vij Senthilnathan, a PTC leader in clinical operations working on the small molecule therapy PTC743 (vatiquinone), now in a Phase 3 global clinical trial for patients with mitochondrial disease and associated refractory epilepsy – a.k.a. the MIT-E Trial, small measurements keep her motivated: “Every cell in the body of a child with mitochondrial epilepsy can be affected by this rare disease,” she explains.

Click here to read the full article and learn more about the MIT-E Study.